BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Filters
Save & Share
Clear Filters
Location
Explore options near your home - or near family and friends.
Diagnosis
MDS Centers of Excellence
Near Add Your Location
Sorting 7 by
MDS Center of Excellence
A Center of Excellence as recognized by the MDS Foundation, is a hospital that has demonstrated its commitment to MDS research. This is accomplished by conducting specialized genetic testing, offering ongoing clinical trials for MDS patients, and actively participating in peer-reviewed MDS research.
- Accepting patients
- Show Principal Investigator
- Accepting patients
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
520 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.